麻豆传媒

Dr. Neal Saab is Senior Science Program Manager for the Institute for Advancement of Food and Nutrition Sciences (IAFNS) where he leads the research and outreach efforts in several areas including caffeine, food chemical safety, and food and packaging safety and sustainability. Dr. Saab has broad experience engaging regulatory agencies on environmental risk assessment of chemicals and also managed science committees focused on exposure and toxicology. Dr. Saab has a strong research background in plant science and biotechnology and has been awarded two patents for his innovations. He received his PhD in Crop聽Science聽from Cornell University.

Dr. Caitlin Karolenko, PhD is a Scientific Program Manager at the Institute for the Advancement of Food and Nutrition Sciences (IAFNS). In this role, Dr. Karolenko leads various food safety initiatives including the Food Microbiology Committee. Additionally, she manages organizational projects to promote and enhance scientific integrity in the food and nutrition research process. Dr. Karolenko received her PhD in Food Science with a concentration in Food Microbiology from Oklahoma State University. She has direct experience with process validation including pathogen inhibition and microbiome analysis. 

Dr. Vinka Oyanedel-Craver is a Professor at the Department of Civil and Environmental Engineering at the University of Rhode Island. Her research interests lie in the area of emerging contaminants of drinking water, wastewater, and stormwater treatment, as well as the development of novel water technologies. Her current research focus is on environmental nanotechnology, specifically on the behavior and application of nanomaterials in different ecological compartments and their use as antimicrobial compounds in point of use water/wastewater treatment in rural developing communities. Her research team has authored more than 45 peer-review publications. 

Dr. Akanda鈥檚 primary expertise is in the intersections of Water Security, Climate Change and Global Health 鈥� and the development of early warning systems to benefit emerging public health issues in the developing world. Ali was the recipient of the NIH Ruth Kirschstein Predoctoral Fellowship and the Dean鈥檚 Fellowship during his PhD at Tufts University, Medford, MA. Ali鈥檚 doctoral research was the first to identify both dry and wet season hydroclimatic drivers of cholera outbreaks in South Asia and was instrumental in securing an NIH Research Challenge Grant on climate change impacts on cholera. His current research focuses on providing a large scale understanding of hydroclimatic forces affecting water-related disease outbreaks in resource constrained regions, and understanding health impacts of climatic and anthropogenic changes in rapidly growing urban regions of developing nations.

Dr. Goodwill is an Assistant Professor in the Civil and Environmental Engineering Department in the College of Engineering at the University of Rhode Island, a position he started in the fall of 2017. In this appointment, he executes research in physicochemical processes, water quality, and water-poverty issues. He also teaches classes focused on water treatment and reuse, and environmental analytical techniques. His Ph.D. and M.S. degrees in Civil and Environmental Engineering are from the University of Massachusetts Amherst. He also holds a B.S. in Civil Engineering from Lafayette College. Prior to entering academia, Joe was a Project Engineer for Black & Veatch working on global projects out of their Philadelphia office. He is a licensed Professional Engineer (PE), and a Leadership in Energy and Environmental Design (LEED) Accredited Professional. Joe also works with multiple international water NGOs, supporting projects in Malawi, India, Ghana, and Bolivia. He received an NSF Faculty Early Career Development Award in 2021.

Dr. Boving is a Professor of Environmental Hydrogeology in the University of Rhode Island College of the Environment and Life Sciences with a join appointment in the College of Engineering Department of Civil and Environmental Engineering and Geosciences. His research focuses on the fate, transport, and remediation of organic and inorganic pollutants from point- and non-point sources. He is specifically interested in water treatment, soil and groundwater remediation and water resources in developing countries - including attenuating the adverse effects of stormwater runoff from roads and urbanized areas. Boving is a recipient of a prestigious Fulbright-Nehru Academic and Professional Excellence Award sponsored by the U.S. State Department鈥檚 United States-India Educational Foundation. He is currently teaching at the Indian Institute of Technology Roorkee, one of the oldest and most renowned technical institutions in South Asia, while conducting research on technologies aimed at cleaning up polluted groundwater and soil. 

Dr. Ryan Jensen's lab is focused on the DNA Double Strand Break (DSB) repair response in mammalian cells. DNA DSB鈥檚 are critical lesions for a cell and can lead to cell death if left unrepaired. Alternatively, if repaired incorrectly, a DSB can result in mutagenic consequences leading normal cells down a path to tumorigenesis. He and his team are currently investigating the role BRCA2 (breast cancer susceptibility gene 2) plays in the DSB response as well as its role in homologous recombination (HR). People who inherit a deleterious mutation in the BRCA2 gene are at an incredibly high lifetime risk for breast, ovarian, and other types of cancer. He is particularly interested in the molecular pathogenic events that lead to such a high risk for cancer in the absence of functional BRCA2.

Atalia Omer is professor of religion, conflict and peace studies at the Kroc Institute for International Peace Studies, Keough School of Global Affairs, at the University of Notre Dame. She earned her Ph.D. in religion, ethics and politics (November 2008) from the Committee on the Study of Religion at Harvard University. Her research focuses on religion, violence and peacebuilding as well as theories and methods in the study of religion and Palestine and Israel. 

She was a 2017 Andrew Carnegie Fellow resulting in "Decolonizing Religion and Peacebuilding" (forthcoming with Oxford University Press). Conversing with decolonial scholarship across multiple fields of study, this forthcoming book examines, through an extensive empirical work in Kenya and the Philippines, how and why the practices of religion, peacebuilding and development both reinforce and exceed global structural, neocolonial and epistemic forms of violence. The book traces why a consolidation of the industry of religion and peacebuilding (or the 鈥渉armony business鈥�), in the intersection of neoliberalism and an orientalist security discourses, disempowers religious action at the same time that it empowers religious actors. It exposes another ironic insight: 鈥渕ore is less,鈥� meaning that rather than enhancing religious literacy, the 鈥渉armony business鈥� diminishes hermeneutical horizons. Even as a growing focus in the policy world on the 鈥済lobal engagement with religion鈥� bills itself as a paradigm shift away from a secularist ignorance of the causal capacities of religious actors, meanings, networks and institutions, this increased investment in 鈥渆ngaging鈥� with religion is utilitarian. It focuses much more on function or doing religion or being religious as a matter of communal boundaries, rather than on content or knowing religious traditions as living and contested sites of interpretations and reimagining. Yet, the decolonial and intersectional lens cannot obscure the existence of the multiple religious actors in the global South and their participation in projects of survival, which includes investing in interreligious and intercultural peacebuilding actions. Such religious actors generate decolonial openings regardless of being firmly grounded in closed rather than hermeneutically open or fluid accounts of their religiosity and communal narratives. They should not be theorized away. Analyzing their work offers an opportunity to rethink the study of religion, violence and peace practices, their relevance to theory and theory鈥檚 relevance to them.

Omer鈥檚 first book, "When Peace is Not Enough: How the Israeli Peace Camp Thinks about Religion, Nationalism and Justice" (University of Chicago Press, 2015), examines the way the Israeli peace camp addresses interrelationships between religion, ethnicity and nationality, and how it interprets justice vis-脿-vis the Palestinian conflict. This work scrutinizes the 鈥渧isions of peace鈥� and the 鈥渧isions of citizenship鈥� articulated by a wide spectrum of groups, ranging from Zionist to non-Zionist and secular to religious orientations.

Omer鈥檚 second solo-authored book project, "Days of Awe: Reimagining Jewishness in Solidarity with Palestinians" (University of Chicago Press, 2019), explores why divergences in conceptions of national identity between 鈥渉omeland鈥� and 鈥渄iasporas鈥� could facilitate the proliferation of loci of analysis and foci of peacebuilding efforts, which are yet under-explored both in peace studies and specific scholarship addressing the relations between diasporas and conflict. As a locally situated, distant issue movement, Jewish Palestine solidarity offers a grassroots critique and a transformative agenda for the local Jewish-American landscape while also critiquing Israeli policies and Zionist interpretations of Jewish identity. This book examines the intentional participation of this movement in intra-traditional work that seeks to provincialize Zion from Jewish identity and inter-traditional work that seeks to undo the intersections between Islamophobia in the U.S. and the marginalizing and silencing of lives in Palestine.

Inter-traditional work is also examined as pivotal to the movement鈥檚 efforts to deconstruct the conflation of critique of Israeli policies with anti-Semitism. Likewise, the movement participates in a broader, intersectional solidarity analysis that connects Palestinian struggles with other sites of injustice, both locally and globally, from #BlackLivesMatter to protests against the wall between the U.S. and Mexico.

Omer has published articles in the Journal of the American Academy of Religion; the Journal of Religious Ethics; Soundings: An Interdisciplinary Journal; the Journal of Political Theology; the Study of Nationalism and Ethnicity; the International Journal of Peace Studies; Critical Sociology; Critical Theory of Religion; The Review of Faith and International Affairs; and Method & Theory in the Study of Religion.

Omer is also a Senior Fellow at Harvard Divinity School鈥檚 Religion and Public Life鈥檚 Religion, Conflict and Peace Initiative. She was the recipient of a research fellowship from the Notre Dame Institute for Advanced Studies (Fall 2011), Charlotte W. Newcombe鈥檚 Doctoral Dissertation Fellowship (2007) and Harvard University Merit Fellowship (2006). She was a doctoral fellow at the Center for the Study of World Religions at Harvard University (2002-2004) and a Graduate Associate at the Weatherhead Center for International Affairs at Harvard University (2006-2008).

Professor Heidi Hardt is an Associate Professor of Political Science at the University of California, Irvine and a NATO expert, who is frequently invited to NATO-sponsored and NATO-related events. She was working as a fellow for the NATO Desk at the State Department at the time that the war in Ukraine broke out. Professor Hardt is also the author of the book NATO's Lessons in Crisis (Oxford University Press), as well as numerous articles and book chapters on NATO. The fellowship that she recently completed is referred to as the Council on Foreign Relations International Affairs Fellow (CFR-IAF TIRS). As part of this same fellowship, she worked for Senator Chris Van Hollen, a member of the Europe & Regional Security Subcommittee of the Senate Foreign Relations Committee. Professor Hardt is also the author of Time to React: The Efficiency of International Organizations in Crisis Response. Her research examines transatlantic security, European security and defense, NATO, the EU and OSCE. Issue areas include international organizations, collective defense, crisis management, military operations (e.g. Afghanistan), coalition warfare, strategy, learning, adaptation, organizational change, gender and diplomacy.

Barbara Burtness, MD is a Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Division Chief for Head and Neck/Sarcoma Oncology, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advanc, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition. 

Patricia LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University鈥檚 Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Molly Guthrie serves as Vice President, Policy and Advocacy, where she advances Susan G. Komen’s key legislative and regulatory objectives at the federal, state, and local levels. In this capacity, she is also responsible for leading Komen’s Center for Public Policy and ensuring its work is aligned with meeting the most pressing needs of the breast cancer community. Komen’s legislative efforts focus on policy campaigns to increase funding for medical research and screening programs and ensuring access to affordable, high-quality breast health and cancer care services. In addition to working on policy campaigns, Molly’s team recruits grassroots volunteers across the country to give a personal voice to Komen’s policy and advocacy priorities. Molly joined Susan G. Komen in 2009. Prior to joining Komen, Molly attended the University of Kansas where she received her Bachelor of General Studies with an emphasis on political science and communication studies. She worked in the Offices of Governor Kathleen Sebelius, Congressman Dennis Moore, and the Kansas Health Policy Authority during college.

A graduate of The University of Texas at Austin (BBA), and the University of Houston (MBA and PhD degrees), Gilbert is a fellow in the U.S. Academy on Workplace Bullying, Mobbing, and Abuse. She is the author of How to Transform Bullies into Allies (Information Age Publishing, 2020).

She assists companies in transforming their workplace by helping them recognize dysfunctional patterns and substituting them with compassionate behavior. Her focus on continuous learning and organizational proactivity is designed to overhaul toxic culture and create a welcoming workplace environment that is inclusive of all people.

Her teaching and research emphases include diversity management, online education, and bullying prevention. She is a recipient of the State Farm Excellence Professorship, and the MTSU Outstanding Achievement in Instructional Technology award.  

Her articles on gender, online learning, diversity, race relations, and international business have been featured in journals like The Academy of Management Executive, Journal of Online Learning and Teaching, Journal of Business Education, Group and Organization Management, the Journal of Business Ethics, and as a case study ("Formally Shaming White Criminals") by Harvard Business School.

Gilbert has been featured in Forbes, the Huffington Post, WalletHub, The Workplace Bullying Institute website, Men's Health, Game On庐 Business Talk Radio | VoiceAmerica鈩�, WMOT radio, WGNS radio, The Tennessean, and The Daily Business Journal.

She has recently served as a member of Tennessee Healthy Workplace Advocates, which worked toward passage of the Healthy Workplace Act in Tennessee, TACIR (Tennessee Advisory Commission on Intergovernmental Relations) Workplace Civility Work Group, the MTSU Non-violence Committee, and the Jones College of Business Professionalism Workgroup.

 

Dr. Terletska is a computational physicist working on Quantum Materials with strong electron-electron interactions and disorder. 
She was selected for a National Science Foundation Early Career Development (CAREER) award for her "Beyond Ideal Quantum Materials: Understanding the Critical Role of Disorder and Electron-Electron Interactions"project (2020-2025).
Materials that she studies include Mott insulators, high-temperature superconductors, disordered insulators, topological materials, systems exhibiting quantum criticality. 
In her computations, she uses Quantum Monte Carlo method, Dynamical Mean Field Theory, Distance of the Closest Approach,  The Dynamical Cluster Approximation .
She serves as a mentor of Women studying physics and was the recipient of the 2019 Woman in STEM award at Middle Tennessee State University.
She was also recognized with the prestigious Kavli Institute for Theoretical Physics Scholar Award.
Terletska's areas of expertise include: condensed matter theory; computational many-body physics;
strongly correlated electrons; quantum criticality, disordered systems and localization; metal-Insulator transitions; and superconductivity.
PHD, Florida State University (2011)
MS, Minnesota State University, Mankato (2005)
BS, Drohobych Ivan Franko State Pedagogical University (2002)









































































































































































 

Maryam Lustberg, MD, MPH, is Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of 鈥淩egional Top Doctors,鈥� and 鈥淓xceptional Women in Medicine鈥� for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program.

With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship.
Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters.
Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master's in Public Health from The Ohio State University in 2013.
Education & Training
MPH
The Ohio State University, Clinical Investigation (2010)
MD
University of Maryland (2003)
Departments & Organizations
Cancer Prevention and ControlCenter for Breast CancerCOPPER CenterInternal MedicineMedical OncologySubset Medical Oncology FacultyYale Cancer CenterYale Medicine

Mehra Golshan, MD, MBA, is a cancer surgeon and a nationally and internationally recognized leader in breast cancer treatment and research. In addition to caring for patients, he serves as Deputy Chief Medical Officer for Surgical Services and Clinical Director of the Breast Cancer Program for the Yale Cancer Center, Smilow Cancer Hospital, and Smilow Cancer Hospital Care Centers.
Dr. Golshan also serves as the Executive Vice Chair for Operations in the Department of Surgery and Professor of Surgical Oncology at the Yale School of Medicine.
Dr. Golshan is a leader in the research with over 150 peer reviewed publications. He has led numerous Phase I, II and III clinical trials and translational science innovations impacting the treatment options and outcomes for women. He is an innovator in tailoring surgery and therapy for women with early stage breast cancer with funding support from the Breast Cancer Research Foundation and National Institutes of Health. He is the principal investigator of several phase II trials aiming to reduce the need for second surgeries or re-excisions in women with breast cancer, one of which uses innovative image-guided operating room capabilities to capture and remove all residual tumor utilizing MRI and mass spectrometry which is used at Yale鈥檚 hybrid operating room.
Dr. Golshan prides himself on being an educator having trained and mentored over a hundred breast surgical fellows as well as international surgeons. He has lectured and taught surgeons, trainees and students nationally and internationally in the field of oncology and breast cancer treatment.
Dr. Golshan is a Board Member of the National Accreditation Program for Breast Centers (NAPBC), Chair of NAPBC Education Committee, Chair of the American College of Surgeons Committee on Interprofessional Education and Practice, and Chair of the American Society of Breast Surgeons Question of the Week Committee.
Dr. Golshan completed his fellowship in breast surgical oncology at Northwestern Memorial Hospital. He earned his Medical Degree from Case Western Reserve University School of Medicine and an MBA at Massachusetts Institute of Technology, Sloan School of Management in Cambridge Massachusetts.
Prior to joining Yale, he spent 17 years in Boston at Harvard鈥檚 Brigham and Women鈥檚 Hospital, Dana Farber Cancer Institute where he was the inaugural and incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology. He also served as the Director of the Breast Surgical Oncology Fellowship at the Dana-Farber Cancer Institute/Brigham and Women鈥檚 Hospital/Massachusetts General Hospital and was an Associate Professor of Surgery at Harvard Medical School.
Dr. Golshan鈥檚 approach to breast cancer treatment is through a specialized team approach. For each new patient, Smilow brings together a team of medical oncologists, radiation oncologists, reconstruction surgeons, pathologists, genetics, breast imagers, radiologists, program nurses, and a robust clinical research program. 鈥淚 work closely with so many colleagues dedicated deeply to treating and curing breast cancer who inspire me to be a better physician, scientist, and person every day."

Education & Training
MBA
MIT (2019)
Fellow
Northwestern Memorial Hospital (2003)
Resident
Rush Presbyterian St. Luke's Medical Center (2002)
MD
Case Western Reserve University (1996)

am board certified in both medical oncology and hospice and palliative medicine, which I feel helps me treat the "whole person" and not just a disease. As the Chief Patient Experience Officer at Smilow Cancer Hospital, I enjoy thinking about improving care, especially where the provider and patient experience overlaps. As a breast oncologist, I have a busy practice and enjoy taking care of women with newly diagnosed breast cancer. As the director of the Yale Survivorship Clinic, one of the nation鈥檚 only multi-disciplinary clinics specializing in cancer survivorship, I learn from patients about key issues after treatment and this informs my role as Chair of the NCCN Survivorship Guidelines. My research focuses on healthy lifestyles and quality of life after cancer. I am a facilitator for Relationship-Centered Communication Workshop that address how we develop therapeutic relationships with our patients and each other.
Learn more about Dr. Tara Sanft>>
Education & Training
Fellowship
Northwestern University, Chicago, Illinois (2010)
Fellowship
Northwestern University, Chicago, Illinois (2010)
Resident
Northwestern University Feinberg School of Medicine (2007)
MD
Medical College Wisconsin (2004)

Dr. Greenup is an Associate Professor of Surgery (Oncology) and Chief of Breast Surgical Oncology. She provides coordinated, state-of-the-art care to patients with benign and malignant diseases of the breast as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center.
Learn more about Dr. Greenup
She earned her undergraduate degrees in Zoology and Psychology at the University of Wisconsin, where she also completed a Master of Public Health. She received her medical degree from the Medical College of Wisconsin where she also completed her General Surgery residency, and went on to complete a fellowship as part of The Massachusetts General Hospital, Dana-Farber Cancer Institute and Brigham and Women's Hospital Breast Surgery Fellowship.
Prior to joining Yale, Dr. Greenup was an Associate Professor of Surgery and Population Health Sciences at the Duke University School of Medicine and Duke Cancer Institute. There she founded the Duke Breast Cancer Outcomes Research Group, and Core Faculty for the Duke Margolis Center for Health Policy. In 2016, she received the National Institutes of Health Building Interdisciplinary Research Careers in Women鈥檚 Health (BIRCWH) Award to evaluate how financial costs and burden relate to preference-sensitive decisions for breast cancer surgery. In 2017, she was named the American College of Surgeons and the American Society of Breast Surgeons Health Policy Scholar. Her research focuses on aligning patient-centered care with high-quality, lower cost treatment. She serves on several national committees, including the Alliance in Clinical Oncology Ethics and Value Committees, the American College of Surgeons Cancer Care Delivery Task Force, the American Society of Breast Surgeons Legislative Committee, and the Editorial Board for the Annals of Surgical Oncology.

Education & Training
MD
Medical College of Wisconsin (2009)
MPH
University of Wisconsin (2009)

Dr. Silber is the Associate CEHE Director for Clinical Research. As a medical oncologist who serves as the Medical Director and Physician Champion of the Centers for Disease Control/Connecticut Department of Public Health's 5-year provider supported grant at Yale New Haven Hospital entitled, The Connecticut Cancer Screening Program (CCSP), she designed the Comprehensive Breast Cancer Outreach and Support Program for Underserved Women, which is a culturally competent program supported by the Breast Cancer Alliance of Greenwich. She has supervised Community Health Educators dating back to 1996, when she received a national Komen award for the Sister to Sister Program, and has been recognized for expertise in breast cancer among African American women. She has directed a cancer clinic for the uninsured and underinsured for two decades and have formed community relationships, which require many years to nurture and demonstrate constancy. This year, she became the principal investigator of the Avon-Pfizer Metastatic Breast Cancer Grants Program: Identify-Amplify-Unify. This program assists organizations that provide information and services to help patients in navigating the medical and emotional challenges associated with their disease. Dr. Silber was awarded this grant from a highly competitive pool of 23 non-profit organizations nationally. Also, this year, CT Health and Educational Facilities Authority (CHEFA) awarded a grant to fund a novel program called 鈥淏reast Cancer S.W.A.T. Team- We鈥檝e got your back!鈥�.
Learn more about Dr. Silber>>
As a principal investigator, she assists economically disadvantaged breast cancer patients to adhere to treatment using medical legal partnership. This year, she was selected to participate as a leadership fellow of the Connecticut Health Foundation. The fellowship was established in 2005, and brings together diverse individuals from multiple sectors who are dedicated to achieving health equity. Each year, the foundation selects up to 20 participants into this competitive ten-month program. Throughout this program, her project has been to increase clinical trial participation among ethnic minorities and capitalize on opportunities created by the Affordable Care Act.
On May 1, 2015, she was named Assistant Clinical Director for Diversity and Health Equity at Yale Cancer Center and focuses on engagement with community partners in improving education for prevention and screening and access to cancer care for diverse populations within the local community as well as Greater New Haven area. 

Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Education & Training
Resident
Memorial Sloan-Kettering Cancer Center (2012)
Intern
Memorial Sloan-Kettering Cancer Center (2008)
MD
Yale University School of Medicine (2007)
PhD
Yale University Graduate School (2005)
BS
Yale University (1998)